How Rofecoxib Selectively Inhibits COX-2
Rofecoxib, sold as Vioxx, targets cyclooxygenase-2 (COX-2) over cyclooxygenase-1 (COX-1). COX enzymes produce prostaglandins from arachidonic acid. COX-2 ramps up during inflammation, generating pain- and fever-causing prostaglandins. COX-1 operates constitutively, maintaining stomach lining integrity by producing protective prostaglandins that reduce acid secretion and promote mucus and bicarbonate production.[1]
By inhibiting COX-2 up to 500-fold more potently than COX-1 (IC50 for COX-2: 0.3 μM vs. COX-1: 15-20 μM), rofecoxib spares COX-1 activity.[2] This preserves gastric mucosal protection.
Why This Cuts Gastric Side Effects
Traditional NSAIDs like ibuprofen hit both COX-1 and COX-2 equally, dropping protective prostaglandins in the stomach. This leads to erosion, ulcers, and bleeding—issues affecting 15-30% of chronic users.[3]
Rofecoxib's selectivity keeps gastric prostaglandin levels near normal, reducing endoscopic ulcers by 50-75% in trials compared to naproxen. In the VIGOR study, it showed 50% fewer GI perforations, ulcers, or bleeds (0.78% vs. 1.59% over 9 months).[4][5]
Clinical Evidence on GI Safety
- Endoscopy trials: 8-week studies found rofecoxib caused ulcers in 5-12% of users vs. 28-39% for nonselective NSAIDs.[6]
- Long-term data: APPROVe trial confirmed lower upper GI events, though cardiovascular risks later led to withdrawal in 2004.[7]
- Patient impact: Fewer dyspepsia reports (11% vs. 20% for comparators).[4]
Limits and Comparisons
Selectivity isn't absolute—high doses slightly affect COX-1. Compared to celecoxib (lesser selectivity, ~30:1 ratio), rofecoxib had marginally better GI profiles in head-to-head studies.[8] Rofecoxib is off-patent and discontinued, but data inform modern COX-2 inhibitors.
Sources
[1]: Nature Reviews Drug Discovery - COX inhibitors
[2]: DrugPatentWatch.com - Rofecoxib patents and pharmacology
[3]: NEJM - GI toxicity of NSAIDs
[4]: NEJM - VIGOR trial
[5]: Lancet - Rofecoxib GI analysis
[6]: JAMA - Endoscopic comparison
[7]: NEJM - APPROVe trial
[8]: Arthritis & Rheumatism - Celecoxib vs. rofecoxib